Belite Bio

What Belite Bio does

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule therapeutics built on a proprietary Retinol Binding Protein 4 (RBP4) antagonist platform. The company's lead asset, Tinlarebant (LBS-008), is a once-daily oral therapy designed to lower serum RBP4, the sole carrier of retinol from the liver to the eye, thereby reducing accumulation of cytotoxic bisretinoids that drive retinal cell death. Tinlarebant is being advanced in adolescent Stargardt disease type 1 (Phase 3 DRAGON, with a 35.7% reduction in lesion growth rate vs. placebo) and Geographic Atrophy secondary to dry AMD (Phase 3 PHOENIX), with a completed rolling NDA submission to the FDA in June 2026. A second preclinical candidate, LBS-009, applies the same RBP4 mechanism to metabolic diseases (NAFLD, NASH, Type 2 diabetes).

The company is headquartered in San Diego, California, was founded in 2018, trades on NASDAQ under BLTE, and is controlled by Lin BioScience, Inc. (TPEx: 6696). Belite has accumulated FDA Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy, and Fast Track designations, plus parallel EU, UK (conditional marketing authorization), Japan (Orphan and Sakigake), and China (priority review) pathways, reflecting a global multi-jurisdiction regulatory strategy.

Belite is pre-revenue with zero product sales in 2021-2025 and a FY2025 GAAP net loss of $77.6M. Revenue mechanics are not yet in operation: the company is building a 25-30 person U.S. specialty field force and pursuing a Q1 2027 U.S. commercial launch of Tinlarebant, with estimated per-patient annual pricing around $350,000. As of Q1 2026, Belite holds $798.6M in cash, cash equivalents, and U.S. treasury holdings, providing roughly 7-8 years of runway at current burn and supporting both the U.S. launch and the LBS-009 IND-enabling program.

Name

Belite Bio

Legal name

Belite Bio, Inc.

Website

https://belitebio.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Belite Bio is a clinical-stage biopharmaceutical company developing once-daily oral RBP4 antagonist therapies, led by Tinlarebant for Stargardt disease type 1 and Geographic Atrophy, with an FDA NDA submission completed in June 2026 and a planned 2027 U.S. launch.

Ownership category

akta.pro rank

Product category

Ophthalmic Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB)

akta.pro secondary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Retinal disease therapeutics
• Clinical stage biopharmaceuticals
• Oral RBP4 antagonist therapy
• Ophthalmic drug development
• Rare disease pharmaceuticals

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Belite Bio is a clinical-stage biopharmaceutical company with no current revenue. The company is preparing for commercialization of Tinlarebant for Stargardt disease and geographic atrophy, with potential FDA approval expected in Q1 2027. The company has plans to build commercial infrastructure and launch the product in the US and international markets.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Belite Bio is a clinical-stage biopharmaceutical company developing a pipeline of novel once-daily oral therapies built on its proprietary RBP4 (Retinol Binding Protein 4) antagonist platform. Its lead candidate Tinlarebant (LBS-008) targets retinal degenerative diseases including Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA), while LBS-009 is in preclinical development for metabolic diseases such as NAFLD, NASH, and Type 2 diabetes. The company has completed a rolling NDA submission to the FDA for Tinlarebant and holds Orphan Drug, Breakthrough Therapy, Rare Pediatric Disease, and Fast Track designations.

Product overview

Belite Bio is a clinical-stage biopharmaceutical company developing a pipeline of novel oral therapies built on its RBP4 (Retinol Binding Protein 4) intellectual property portfolio. The lead product is Tinlarebant (LBS-008), currently in Phase 3 clinical trials for Stargardt disease type 1 and Geographic Atrophy, with a completed NDA submission to the FDA in 2026. The company also has LBS-009 in preclinical development for metabolic diseases including NAFLD, NASH, and Type 2 diabetes. Both products utilize RBP4 antagonism as a mechanism of action to treat degenerative conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Tinlarebant (LBS-008) Novel once-daily oral therapy that reduces accumulation of toxins in the eye causing Stargardt disease type 1 (STGD1) and contributing to Geographic Atrophy (GA). Works by reducing serum retinol binding protein 4 (RBP4) levels, the sole carrier protein for retinol transport from liver to eye. Currently in Phase 3 development with completed rolling NDA submission to the FDA under Breakthrough Therapy Designation. Has obtained Orphan Drug Designation in the United States, Europe, and Japan, and Rare Pediatric Disease, Breakthrough Therapy, and Fast Track designations in the US, and Sakigake designation in Japan.
• LBS-009

Quantifiable outcome

• 35.7% statistically significant reduction in macular lesion growth rate vs placebo in Phase 3 DRAGON trial
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Prevent BlindnessminorGTM or Marketing Partner · 27 April 2026Belite Bio is a Gold Sponsor of Prevent Blindness Inherited Retinal Disease (IRD) and Genetic Testing Month. The initiative provides free resources to patients on conditions including Stargardt Disease and the importance of genetic testing for early diagnosis and treatment planning.

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Alkeus Pharmaceuticals: Alkeus is developing gildeuretinol (ALK-001), an oral modified vitamin A for Stargardt disease — the most direct clinical competitor to Belite's Tinlarebant in STGD1. Both companies target the same inherited juvenile macular degeneration with orally bioavailable disease-modifying mechanisms and are racing for first approval.
• Aldeyra Therapeutics: Aldeyra is a clinical-stage biotech developing novel small-molecule therapies for retinal diseases and inflammatory ocular conditions. Like Belite, Aldeyra pursues orally administered disease-modifying mechanisms in ophthalmology, making it a close comparable in stage, modality, and target indication.

Broad incumbents

• Apellis Pharmaceuticals: Apellis markets Syfovre (pegcetacoplan), an FDA-approved intravitreal complement inhibitor for Geographic Atrophy — the established injectable incumbent Belite will compete against if Tinlarebant reaches the GA market. Same GA indication, broader commercial footprint.
• Astellas Pharma (Iveric Bio): Astellas acquired Iveric Bio and now markets Izervay (avacincaptad pegol), the second FDA-approved GA therapy and direct competitor to Syfovre. Represents the second major injectable GA incumbent that Belite's oral Tinlarebant would compete against in the Phase 3 PHOENIX indication.
• Regeneron Pharmaceuticals: Regeneron commercializes Eylea (aflibercept), the dominant anti-VEGF therapy in retinal disease including wet AMD and diabetic eye disease. As a broad ophthalmology incumbent with established retinal specialist relationships, Regeneron represents the standard-of-care backdrop against which Belite will compete for physician adoption.
• Roche (Genentech): Roche/Genentech markets Lucentis (ranibizumab) and Vabysmo (faricimab), foundational anti-VEGF therapies in retinal disease. As a global ophthalmology leader, Roche sets the commercial and pricing benchmark for retinal therapeutics that Belite's oral mechanism must disrupt.

Emerging players

• Adverum Biotechnologies: Adverum is developing ADVM-022, a single-injection intravitreal gene therapy for wet AMD. Like Belite, Adverum pursues disease-modifying retinal therapies with a differentiated mechanism, but with an AAV gene therapy delivery approach that complements Belite's oral small-molecule strategy in the broader retinal pipeline.
• Nanoscope Therapeutics: Nanoscope is developing optogenetic gene therapies for inherited retinal diseases including retinitis pigmentosa and Stargardt. Targets overlapping patient populations with a different mechanism (gene therapy vs. RBP4 antagonism), positioning it as a partial-overlap emerging competitor in rare retinal disease.
• ProQR Therapeutics: ProQR develops RNA-based therapies for inherited retinal diseases including Leber congenital amaurosis and Usher syndrome. Similar clinical-stage profile to Belite with a focus on rare ophthalmology indications and a platform approach to genetic eye diseases.
• Kiora Pharmaceuticals: Kiora is a clinical-stage ophthalmology company developing small-molecule and gene therapy approaches for retinal diseases including retinitis pigmentosa and diabetic macular edema. Comparable size, stage, and retinal disease focus to Belite, making it a useful smaller-cap comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Belite Bio